Emergent BioSolutions Inc. (NYSE:EBS) Shares Purchased by Wellington Management Group LLP

Wellington Management Group LLP grew its holdings in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 19.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 136,289 shares of the biopharmaceutical company’s stock after purchasing an additional 22,295 shares during the quarter. Wellington Management Group LLP’s holdings in Emergent BioSolutions were worth $1,138,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. State Street Corp boosted its position in Emergent BioSolutions by 864.7% during the third quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock worth $15,960,000 after acquiring an additional 1,713,200 shares during the last quarter. Millennium Management LLC lifted its stake in Emergent BioSolutions by 5.8% in the 2nd quarter. Millennium Management LLC now owns 946,302 shares of the biopharmaceutical company’s stock worth $6,454,000 after purchasing an additional 52,144 shares in the last quarter. American Century Companies Inc. lifted its stake in Emergent BioSolutions by 240.9% in the 2nd quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock worth $6,015,000 after purchasing an additional 623,201 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in Emergent BioSolutions by 74.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock worth $6,192,000 after purchasing an additional 316,700 shares in the last quarter. Finally, Marshall Wace LLP boosted its holdings in shares of Emergent BioSolutions by 75.4% during the 2nd quarter. Marshall Wace LLP now owns 542,813 shares of the biopharmaceutical company’s stock worth $3,702,000 after purchasing an additional 233,341 shares during the last quarter. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

EBS has been the topic of a number of analyst reports. Benchmark lifted their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. StockNews.com lowered Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Friday. Finally, Rodman & Renshaw reissued a “buy” rating and issued a $16.00 price objective on shares of Emergent BioSolutions in a report on Friday, September 13th.

Emergent BioSolutions Trading Down 1.2 %

EBS opened at $8.06 on Friday. The stock has a market capitalization of $436.72 million, a PE ratio of -1.97 and a beta of 1.59. Emergent BioSolutions Inc. has a one year low of $1.42 and a one year high of $15.10. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The business’s 50 day moving average price is $9.31 and its 200 day moving average price is $8.77.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.